Therefore, an increase in CD38+ and CD31+ EVs in the peripheral blood could predict the progression of MGUS to MM as well as the therapeutic response; thus, avoiding the BM biopsies of patients. This evidence concerns the gene PECAM1 and Miyoshi myopathy.